Showing results (91-100 of 114) with videos related to
Sort By:
Pageof 12
European Urology Oncology|January 4, 2026
Results of the Randomized Phase 3 AFU-GETUG-20 Trial Evaluating Adjuvant Leuprorelin Acetate After Radical Prostatectomy in Men with High-risk Localized Prostate CancerFrançois Rozet, Alain Ruffion, Pablo Lemercier, et al.JNCI Cancer Spectrum|April 16, 2024
Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrationsAndrea Necchi, Rodryg Ramlau, Alejandro Falcón González, et al.Cancer Immunology, Immunotherapy : CII|May 24, 2026
Real-world efficacy and safety of immune checkpoint blockades in advanced urothelial carcinoma with histologic variant subtypes: the pembroblad studyKarim Amrane, Luca Campedel, Fabien Moinard-Butot, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2018
Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial CancerDavid J Vaughn, Joaquim Bellmunt, Yves Fradet, et al.European Journal of Cancer (Oxford, England : 1990)|April 11, 2020
Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE studyAlexis B Cortot, Clarisse Audigier-Valette, Olivier Molinier, et al.European Journal of Cancer (Oxford, England : 1990)|January 18, 2022
Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinomaGuru P Sonpavde, Cora N Sternberg, Yohann Loriot, et al.Nature Medicine|April 8, 2025
Broad versus limited gene panels to guide treatment in patients with advanced solid tumors: a randomized controlled trialOlivier Trédan, Damien Pouessel, Nicolas Penel, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2024
Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial CancerYohann Loriot, Arjun V Balar, Daniel P Petrylak, et al.World Journal of Urology|July 1, 2021
Risk factors associated with positive surgical margins' location at radical cystectomy and their impact on bladder cancer survivalFrancesco Claps, Maaike W van de Kamp, Roman Mayr, et al.European Journal of Cancer (Oxford, England : 1990)|November 29, 2011
A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trialKarim Fizazi, Francois Lesaunier, Remy Delva, et al.Pageof 12